[go: up one dir, main page]

MX2012013206A - Inhibidores de quinasa biciclica fusionada. - Google Patents

Inhibidores de quinasa biciclica fusionada.

Info

Publication number
MX2012013206A
MX2012013206A MX2012013206A MX2012013206A MX2012013206A MX 2012013206 A MX2012013206 A MX 2012013206A MX 2012013206 A MX2012013206 A MX 2012013206A MX 2012013206 A MX2012013206 A MX 2012013206A MX 2012013206 A MX2012013206 A MX 2012013206A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
fused bicyclic
bicyclic kinase
formula
treatment
Prior art date
Application number
MX2012013206A
Other languages
English (en)
Inventor
Andrew Philip Crew
Arno G Steinig
Meizhong Jin
Jing Wang
Andrew Kleinberg
Mark J Mulvihill
An-Hu Li
Original Assignee
Osi Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharmaceuticals Llc filed Critical Osi Pharmaceuticals Llc
Publication of MX2012013206A publication Critical patent/MX2012013206A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de fórmula I, como se muestra abajo y define aquí: (ver Fórmula) sales farmacéuticamente aceptables de los mismos, síntesis, intermedios, formulaciones y métodos de tratamiento de enfermedad, incluyendo el tratamiento de cánceres, tales como tumores impulsados por lo menos en parte por al menos uno de RON, MET o ALK.
MX2012013206A 2010-05-14 2011-05-16 Inhibidores de quinasa biciclica fusionada. MX2012013206A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33473410P 2010-05-14 2010-05-14
PCT/US2011/036572 WO2011143645A1 (en) 2010-05-14 2011-05-16 Fused bicyclic kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2012013206A true MX2012013206A (es) 2012-12-17

Family

ID=44211949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013206A MX2012013206A (es) 2010-05-14 2011-05-16 Inhibidores de quinasa biciclica fusionada.

Country Status (19)

Country Link
US (2) US8445510B2 (es)
EP (1) EP2569314B1 (es)
JP (1) JP5820472B2 (es)
KR (1) KR20130118213A (es)
CN (1) CN102971316A (es)
AR (1) AR081039A1 (es)
AU (1) AU2011252784A1 (es)
BR (1) BR112012028674A2 (es)
CA (1) CA2790847A1 (es)
EA (1) EA201291246A1 (es)
ES (1) ES2604481T3 (es)
MX (1) MX2012013206A (es)
PH (1) PH12012502102A1 (es)
PL (1) PL2569314T3 (es)
PT (1) PT2569314T (es)
SG (1) SG184822A1 (es)
TW (1) TW201141863A (es)
WO (1) WO2011143645A1 (es)
ZA (1) ZA201208489B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592448B2 (en) * 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
CA2807093A1 (en) * 2010-08-05 2012-02-09 Amgen Inc. Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
EP2710003A1 (en) * 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2867233A1 (en) * 2012-07-03 2015-05-06 Aurigene Discovery Technologies Limited 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
CN103613591B (zh) * 2012-09-29 2016-04-13 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
TWI498325B (zh) * 2013-01-18 2015-09-01 Hoffmann La Roche ３－取代吡唑及其用途
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
KR102244719B1 (ko) 2013-03-15 2021-04-26 플렉시콘 인코퍼레이티드 헤테로시클릭 화합물 및 그의 용도
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
CN104628555B (zh) * 2015-01-05 2016-11-30 烟台蓓丰医药科技有限公司 一种药物中间体4-(4-氯苯基)环己基-1-甲酸的合成方法
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
AU2018348241B2 (en) 2017-10-13 2023-01-12 Opna Bio SA Solid forms of a compound for modulating kinases
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US20230339937A1 (en) 2020-06-19 2023-10-26 Sato Pharmaceutical Co., Ltd. Condensed ring compounds that inhibit h-pgds

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360531A (en) 1981-04-09 1982-11-23 The Upjohn Company Substituted cycloalkanes
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
AP2003002929A0 (en) 2001-06-23 2003-12-31 Aventis Pharma Inc Pyrrolopyrimidines as protein kinase inhibitors
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
KR20040111445A (ko) 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
ATE331708T1 (de) 2002-12-10 2006-07-15 Wyeth Corp Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor-1 (pai-1) inhibitoren
US7230098B2 (en) 2003-02-26 2007-06-12 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
US7250417B2 (en) 2003-07-02 2007-07-31 Sugen Inc. Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
ES2527118T3 (es) 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
US20050182060A1 (en) 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
AU2005269387A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
JP2008510792A (ja) 2004-08-26 2008-04-10 ファイザー・インク タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
AP2373A (en) 2004-08-26 2012-03-07 Pfizer Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors.
NZ552946A (en) 2004-08-26 2010-09-30 Pfizer Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
NZ563444A (en) 2005-05-17 2011-04-29 Plexxikon Inc Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors
NZ564696A (en) 2005-06-10 2011-05-27 Boehringer Ingelheim Int Glucocorticoid, indazole, mimetics, methods of making them, pharmaceutical compositions, and uses thereof
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
MX2008007049A (es) 2005-11-30 2008-10-23 Vertex Pharma Inhibidores de c-met y usos de los mismos.
JP2009517432A (ja) 2005-11-30 2009-04-30 エフ．ホフマン−ラ ロシュ アーゲー ３−アミノ−２−アリールプロピルアザインドールおよびその使用
US8217057B2 (en) 2005-12-05 2012-07-10 Pfizer Inc. Polymorphs of a c-MET/HGFR inhibitor
EP1963320A1 (en) 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
DK1966214T3 (en) 2005-12-21 2017-02-13 Janssen Pharmaceutica Nv TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
CA2651979A1 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
KR101401811B1 (ko) 2006-08-16 2014-05-29 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 저해제
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US8639558B2 (en) 2006-09-25 2014-01-28 International Business Machines Corporation Providing markdown item pricing and promotion calendar
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
KR20090071612A (ko) 2006-10-23 2009-07-01 에스지엑스 파마슈티컬스, 인코포레이티드 단백질 키나제 조정제로서의 바이시클릭 트리아졸
PL2081937T3 (pl) 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Triazolopirydazynowe modulatory kinaz białkowych
GB0621607D0 (en) 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
RU2009122670A (ru) 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
JP2010516680A (ja) 2007-01-19 2010-05-20 エックスカバリー，インコーポレイテッド キナーゼ阻害薬化合物
TW200908968A (en) 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
CN101903382B (zh) 2007-12-21 2012-11-28 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
KR20100102651A (ko) 2008-01-22 2010-09-24 메르크 파텐트 게엠베하 단백질 키나제 억제제들 및 이의 이용
EP2288383A1 (en) 2008-05-14 2011-03-02 Amgen, Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
MX2011003363A (es) 2008-10-01 2011-04-27 Ludwig Inst Cancer Res Metodos para el tratamiento de cancer.
US8592448B2 (en) * 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
AU2010224245B2 (en) 2009-03-11 2016-07-21 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of Raf kinases
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors

Also Published As

Publication number Publication date
US20110281888A1 (en) 2011-11-17
WO2011143645A1 (en) 2011-11-17
US8445510B2 (en) 2013-05-21
KR20130118213A (ko) 2013-10-29
JP2013526569A (ja) 2013-06-24
EP2569314B1 (en) 2016-09-07
AR081039A1 (es) 2012-05-30
PT2569314T (pt) 2016-10-25
US20130253197A1 (en) 2013-09-26
EA201291246A1 (ru) 2013-04-30
CN102971316A (zh) 2013-03-13
PL2569314T3 (pl) 2017-02-28
SG184822A1 (en) 2012-12-28
ES2604481T3 (es) 2017-03-07
JP5820472B2 (ja) 2015-11-24
PH12012502102A1 (en) 2013-02-11
AU2011252784A1 (en) 2012-09-13
BR112012028674A2 (pt) 2016-08-16
ZA201208489B (en) 2013-09-25
EP2569314A1 (en) 2013-03-20
TW201141863A (en) 2011-12-01
CA2790847A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
CY1121625T1 (el) Αναστολεις prmt5 και χρησεις αυτων
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
CU24004B1 (es) Peptidomiméticos de smac útiles como inhibidores de proteínas de apoptosis (iap)
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CY1120258T1 (el) Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος
CR20120460A (es) Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
UY38712A (es) Lactamas fusionadas de arilo y heteroarilo
DOP2014000058A (es) 3- pirmidin- 4- il- oxazolidin- 2- onas como inhibidores de la idh mutante
CU24335B1 (es) Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
BR112012029647A2 (pt) novos derivados de pirimidinas
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
PH12015500376B1 (en) Novel bicyclic pyridinones
GB201209587D0 (en) Therapeutic compounds
GT201400100A (es) Formulaciones farmacéuticas
EA201591024A1 (ru) Димерные соединения
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
EA201391206A1 (ru) Способы синтеза производных предшественника молибдоптерина z
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
CL2011001850A1 (es) Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto.
UY30514A1 (es) Compuestos organicos

Legal Events

Date Code Title Description
FG Grant or registration